Safety: Clinical Trials

14 trials for Safety, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed. 14 Phase 2, 6 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 214Completed 14
Phase 16Completed 6
Phase 31Completed 1

Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Anlotinib - Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy
Phase 2CompletedJIANYANG WANG442024-01-012026-10-07
A Study of GC101 TIL in Advanced Melanoma (BZ)
GC101 TIL - Tumor Infiltrating Lymphocytes, Safety
Phase 1 / Phase 2CompletedShanghai Juncell Therapeutics182023-11-082025-12-23
Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection Fraction
Diuretics withdrawal, Diuretics maintenance - Heart Failure, Electric Impedance
Phase 2CompletedMaimónides Biomedical Research Institute of Córdoba982022-12-192024-11-04
A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401
CU-20401 - Safety
Phase 1 / Phase 2CompletedCutia Therapeutics(Wuxi)Co.,Ltd482022-02-272024-12-10
Efficacy of Ivermectin in COVID-19
Ivermectin, Placebo - Safety, SARS-CoV2 Infection
Phase 1 / Phase 2CompletedBangkok Metropolitan Administration Medical College and Vajira Hospital722021-09-012021-12-15
Autologous Adipose Derived Stem Cells Transplantation in the Treatment of Keloids.
Autologous adipose derived stem cells - Keloid, Autologus Adipose Derived Stem Cells
Phase 2CompletedMakerere University82021-03-012021-06-18
EMaBS TB Vaccine Study
ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity
Phase 1 / Phase 2CompletedUniversity of Oxford722019-07-012022-08-05
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
Placebo, XEN-D0501 - Efficacy, Safety
Phase 2CompletedPila Pharma542019-02-252022-04-29
Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants.
Test product, Control product - Subjects in Need of a Human Milk Fortifier (HMF), Growth
Phase 2 / Phase 3CompletedNutricia Research2072018-03-082024-09-26
Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient
Adcetris-Levact - Clinical Efficacy, Safety
Phase 1 / Phase 2CompletedCentre Antoine Lacassagne602016-01-142026-08-31
A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily - Asthma, Efficacy
Phase 2CompletedAstraZeneca542015-06-252018-02-15
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique
HIVIS DNA vaccine, Zetajet, Derma Vax Electroporation - Vaccines, HIV
Phase 2CompletedMuhimbili University of Health and Allied Sciences1982012-11-012015-06-29
Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults
Lactobacillus Reuteri DSM 17938 - Safety
Phase 1 / Phase 2CompletedGood Food Practice, Sweden322012-03-012012-07-04
A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
160U /0.5ml EV71 Vaccine, 320U /0.5ml EV71 vaccine, 640U /0.5ml EV71 vaccine - Immunogenicity, Safety
Phase 2CompletedJiangsu Province Centers for Disease Control and Prevention12002011-07-012012-05-31

Narrower conditions

Asthma (1)  ·  COVID-19 (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Dyspnea (1)  ·  Edema (1)  ·  Heart Failure (1)  ·  Keloid (1)  ·  Melanoma (1)  ·  Tuberculosis (1)

Broader conditions

Respiratory Tract Diseases (4)  ·  Lung Diseases (3)  ·  Infections (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Actinomycetales Infections (1)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Bronchial Diseases (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Cardiovascular Diseases (1)  ·  Chemically-Induced Disorders (1)

Interventions

Adjuvants, Pharmaceutic (1)  ·  Albuterol (1)  ·  Bendamustine Hydrochloride (1)  ·  Brentuximab Vedotin (1)  ·  Control Groups (1)  ·  Ivermectin (1)  ·  MVA 85A (1)  ·  anlotinib (1)  ·  smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1)  ·  velsecorat (1)

Sponsors

AstraZeneca (1)  ·  Bangkok Metropolitan Administration Medical College and Vajira Hospital (1)  ·  Centre Antoine Lacassagne (1)  ·  Cutia Therapeutics(Wuxi)Co.,Ltd (1)  ·  Good Food Practice, Sweden (1)  ·  JIANYANG WANG (1)  ·  Jiangsu Province Centers for Disease Control and Prevention (1)  ·  Maimónides Biomedical Research Institute of Córdoba (1)  ·  Makerere University (1)  ·  Muhimbili University of Health and Allied Sciences (1)  ·  Nutricia Research (1)  ·  Pila Pharma (1)  ·  Shanghai Juncell Therapeutics (1)  ·  University of Oxford (1)

Countries

China (4)  ·  France (2)  ·  Germany (2)  ·  Uganda (2)  ·  United Kingdom (2)  ·  Bulgaria (1)  ·  Lithuania (1)  ·  Mozambique (1)  ·  Netherlands (1)  ·  Spain (1)  ·  Sweden (1)  ·  Tanzania (1)  ·  Thailand (1)

Top investigators

Alberto Torres Zamudio, MD (1)  ·  Andrea Ludwig-Sengpiel, Dr. (1)  ·  Anne-Marie Kirsten, Dr. (1)  ·  Anneliese Linnhoff, Dr. med. (1)  ·  Christine Grigat, Dr. (1)  ·  Dirk Skowasch, Prof. (1)  ·  Dorte X Gram, PhD (1)  ·  Helen McShane, Professor (1)  ·  Johan Olsson, PhD (1)  ·  Jun Guo (1)  ·  Jutta Beier, Dr. med. (1)  ·  Margret Jandl, Dr. (1)  ·  Oliver Kornmann, Dr. (1)  ·  Rainard Fuhr, Dr. med. (1)

Results publications

PMID 21791539, PMID 23352749, PMID 25176015, PMID 28390780, PMID 30121146, PMID 30741494, PMID 30777086, PMID 31424503, PMID 32171764, PMID 32673497, PMID 33736819, PMID 34447992, PMID 36028897, PMID 40037774, PMID 42644287, PMID 42648772

NIH funding

2014 (1), 2018 (1)